Table 2.
Correlation of LINC00961 expression with clinicopathological features in BC patients
| Characteristics | No. of cases | LINC00961 expression | p-value | |
|---|---|---|---|---|
| Low (N = 40) | High (N = 39) | |||
| Age at diagnose | ||||
| ≤ 40 | 20 | 11 (28.9%) | 9 (24.3%) | 0.651 |
| > 40 | 55 | 27 (71.1%) | 28 (75.7%) | |
| Tumor size (cm) | ||||
| < 2 | 21 | 7 (18.9%) | 14 (35.9%) | 0.248 |
| 2–5 | 41 | 22 (59.5%) | 19 (48.7%) | |
| > 5 | 14 | 8 (21.6%) | 6 (15.4%) | |
| Group | ||||
| Luminal A | 65 | 33 (82.5%) | 32 (82.1%) | 0.958 |
| Luminal B | 14 | 7 (17.5%) | 7 (17.9%) | |
| Grade | ||||
| 1 | 10 | 5 (12.5%) | 5 (12.8%) | 0.997 |
| 2 | 55 | 28 (70.0%) | 27 (69.2%) | |
| 3 | 14 | 7 (17.5%) | 7 (17.9%) | |
| Stage | ||||
| I | 6 | 2 (5.3%) | 4 (11.4%) | 0.466 |
| II | 38 | 22 (57.9%) | 16 (45.7%) | |
| III | 29 | 14 (36.8%) | 15 (42.9%) | |
| Pathology of tumors* | ||||
| DCIS | 1 | 1 (4.3%) | 0 (0.0%) | 0.415 |
| IDC | 38 | 21 (91.3%) | 17 (94.4%) | |
| ILC | 1 | 0 (0.0%) | 1 (5.6%) | |
| Others | 1 | 1 (4.3%) | 0 (0.0%) | |
| Progesterone receptor | ||||
| Negative | 10 | 4 (10.0%) | 6 (15.4%) | 0.472 |
| Positive | 69 | 36 (90.0%) | 33 (84.6%) | |
| Estrogen receptor | ||||
| Negative | 0 | 0 (0.0%) | 0 (0.0%) | – |
| Positive | 79 | 40 (100.0%) | 39 (100.0%) | |
| HER2 | ||||
| Negative | 70 | 35 (87.5%) | 35 (89.7%) | 0.754 |
| Positive | 9 | 5 (12.5%) | 4 (10.3%) | |
| Smoking† | ||||
| No | 41 | 18 (81.8%) | 23 (95.8%) | 0.012* |
| Yes | 5 | 4 (18.2%) | 1 (4.2%) | |
†Fisher exact test was used for calculating p-value
*p < 0.05